Skip to main content
An official website of the United States government
Email

Bladder SPORE

Bladder cancer will have an estimated 84,530 new cases and 17,870 deaths in 2026 according to the NCI's Surveillance, Epidemiology, and End Results Program (SEER)*. The percent of patients surviving for 5 years is 79.1%. The incidence rate is about 4 times higher in men than in women and 1.9 times higher in White men than in Black men. 

The Memorial Sloan Kettering Cancer Center Bladder Specialized Program of Research Excellence (SPORE) was funded in 2026 with goals to:

  1. Identify predictive biomarkers of response or resistance to antibody-drug conjugates, immunotherapies, and investigational treatments.
  2. Develop noninvasive blood- or urine-based biomarkers of clinical response and resistance to facilitate personalization of therapy, including dose de-intensification.
  3. Develop more effective novel immunotherapies and immunotherapy-based combinatorial strategies for patients with treatment-resistant urothelial cancer.

Bladder Cancer Statistics
 

  • Reviewed:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Bladder SPORE was originally published by the National Cancer Institute.”

Email